Elsevier Launches Web-Based Pathway Studio and Adds New Molecular Data from Its Biology Journals to Boost Early Discovery Research

ROCKVILLE, Maryland, March 26, 2013 /PRNewswire/ --

Biologists working in life sciences and pharmaceutical research now have access via the Web to molecular data from Elsevier and from articles obtained from other leading publishers

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of a web-based version of Pathway Studio, a research solution for biologists. Additionally, Pathway Studio now incorporates biological data from Elsevier's biology journals in addition to journals obtained through collaboration with third-party publishers. The addition of this data to Pathway Studio results in a resource that is unparalleled in depth and coverage of molecular interactions with supporting evidence. The new web-based version broadly extends access to researchers to reveal new insights and to assist with critical decision making.

"Currently, molecular facts are scattered in individual articles and researchers must gather and integrate these to advance new discovery," said Jaqui Mason, Product Development Director for Biology Products at Elsevier. "Pathway Studio presents these facts in a graphical context to help researchers assemble biological models that can be applied to target discovery programs, identify potential diagnostics, and reposition drugs. The new content included in Pathway Studio can expose a more complete picture in biology, which reduces risk, increases efficiency, and ultimately improves success rate whether it's bringing a new drug to market or exploring a theory."

"Incorporation of facts from Elsevier's biology journals into Pathway Studio, as well as building a pipeline of fresh data through our collaboration with third-party publishers, enables us to deliver additional value to our portfolio of solutions across biology, chemistry, and medicine in order to better serve the needs of customers in early discovery and biology researchers," said Mark van Mierle, Managing Director of Elsevier's Pharma and Biotech Group. "Offering a web-based version of Pathway Studio has allowed us to streamline common tasks and make the benefit of this content accessible to a broader and more general user-base."

The new web-based Pathway Studio adds additional early discovery capability to Elsevier's suite of life science information solutions which include Reaxys, the leading chemistry discovery engine, PharmaPendium which supports regulatory and safety activities, TargetInsights, a biological literature search system for early discovery and Quosa, which automates literature management workflows with applications in pharmacovigilance and medical affairs. This suite effectively delivers complementary solutions spanning early discovery, pre-clinical, clinical and post-launch workflows.

For more information, visit the new Pathway Studio website.

# # #

About Pathway Studio

Pathway Studio is integrated data mining and visualization software with high-quality, comprehensive knowledge bases produced by applying MedScan, Elsevier's proprietary text-mining technology, to a large corpus of biological literature. Pathway Studio allows organizations and researchers to rapidly connect relevant biological facts and relationships, visualize these facts in context, and integrate and interpret experimental data. Pathway Studio is used for defining and testing in silico-based hypotheses across a wide range of disciplines including mechanistic modeling of disease, drug action and toxicity, target discovery and validation, biomarker discovery, cellular and network pathway building, protein-protein interactions and many more.

Pathway Studio is offered in configurations that scale to support individual researchers and global corporations with access to domain specific knowledge bases and cartridges. For more information, visit the Pathway Studio website

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Liz Griffioen
Elsevier
+31-20-485-2247
l.griffioen@elsevier.com

SOURCE Elsevier